Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines). 2015;3:320–43.

O’Hagan DT, Friedland LR, Hanon E, Didierlaurent AM. Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol. 2017;47:93–102.

Article  PubMed  Google Scholar 

Garçon N, Leroux-Roels G, Cheng W-F. Vaccine Adjuvants. In: Garçon N, Stern PL, Cunningham AL, editors. Understanding Modern Vaccines Perspectives in Vaccinology 1. Amsterdam: Elsevier; 2011. p. 89–113.

Giudice GD, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018;2018:14–21.

Article  Google Scholar 

Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37:3167–78.

Article  CAS  PubMed  Google Scholar 

Singleton KL, Joffe A, Leitner WW. Review: Current trends, challenges, and success stories in adjuvant research. Front Immunol. 2023;14:1105655.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16:55–63.

Article  CAS  PubMed  Google Scholar 

James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: the new adjuvanted recombinant herpes zoster vaccine. Ann Pharmacotherapy. 2018;52:673–80.

Article  CAS  Google Scholar 

Lovgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10:401–3.

Article  PubMed  Google Scholar 

Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66:224–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, et al. The Matrix-M adjuvant: A critical component of vaccines for the 21(st) century. Hum Vaccines Immunotherapeutics. 2023;19:2189885.

Article  Google Scholar 

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383:2320–32.

Article  CAS  PubMed  Google Scholar 

Hutter JN, Robben PM, Lee C, Hamer M, Moon JE, Merino K, et al. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults. Vaccine. 2022;40:5781–90.

Article  CAS  PubMed  Google Scholar 

Lawrence J, Kitchin N, Anderson AS, Pride MW, Jansen KU, Gruber WC, et al. Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50–85 years. Vaccine. 2021;39:5991–6003.

Article  CAS  PubMed  Google Scholar 

Melssen MM, Pollack KE, Meneveau MO, Smolkin ME, Pinczewski J, Koeppel AF, et al. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Cancer Immunol Immunother. 2021;70:2151–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Smedt P, Leroux-Roels G, Vandermeulen C, Tasciotti A, Di Maro G, Dozot M, et al. Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial. Vaccine X. 2021;9:100124.

Article  PubMed  PubMed Central  Google Scholar 

Baldwin SL, Reese VA, Larsen SE, Pecor T, Brown BP, Granger B, et al. Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations. Front Microbiol. 2022;13:935444.

Article  PubMed  PubMed Central  Google Scholar 

Bender NG, Khare P, Martinez J, Tweedell RE, Nyasembe VO, Lopez-Gutierrez B, et al. Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen. NPJ Vaccines. 2021;6:49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhatnagar N, Kim KH, Subbiah J, Park BR, Ko EJ, Seong BL, et al. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice. Antiviral Res. 2022;197:105229.

Article  CAS  PubMed  Google Scholar 

Carmen JM, Shrivastava S, Lu Z, Anderson A, Morrison EB, Sankhala RS, et al. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. NPJ Vaccines. 2021;6:151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang CC, Algaissi A, Lai CC, Chang CK, Lin JS, Wang YS, et al. Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus. Vaccine. 2023;41:3337–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellison TJ, Talbott GC, Henderson DR. Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform. Vaccine. 2023;41:304–14.

Article  CAS  PubMed  Google Scholar 

He L, Sun B, Guo Y, Yan K, Liu D, Zang Y, et al. Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants. Int Immunopharmacol. 2021;101:108216.

He X, Zhou S, Huang WC, Seffouh A, Mabrouk MT, Morgan MT, et al. A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8(+) T Cell Epitopes. ACS Nano. 2021;15:4357–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Z, Chen JP, Xu JC, Chen ZY, Qu R, Zhang L, et al. A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination. Virology. 2022;566:56–9.

Article  CAS  PubMed  Google Scholar 

Huang WC, Mabrouk MT, Zhou L, Baba M, Tachibana M, Torii M, et al. Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages. Commun Biol. 2022;5:773.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia Y, Akache B, Agbayani G, Chandan V, Dudani R, Harrison BA, et al. The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model. Pharmaceutics. 2021;13.

King HAD, Joyce MG, Lakhal-Naouar I, Ahmed A, Cincotta CM, Subra C, et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci USA. 2021;118.

Mabrouk MT, Chiem K, Rujas E, Huang W-C, Jahagirdar D, Quinn B, et al. Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice. Sci Adv. 2021;7:eabj1476.

Article  PubMed  PubMed Central  Google Scholar 

Quan DH, Counoupas C, Nagalingam G, Pinto R, Petrovsky N, Britton WJ, et al. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. Vaccine. 2021;39:1990–6.

Article  CAS  PubMed  Google Scholar 

Sei CJ, Rao M, Schuman RF, Daum LT, Matyas GR, Rikhi N, et al. Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies. Vaccines. 2021;9:698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shrivastava S, Carmen JM, Lu Z, Basu S, Sankhala RS, Chen WH, et al. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. NPJ Vaccines. 2023;8:43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thanvi R, Nada S, Dissanayake R, Vartak A, Sebilleau CO, Alom NE, et al. Synthesis and Evaluation of a Self-Adjuvanting Pseudomonal Vaccine Based on Major Outer Membrane Porin OprF Epitopes Formulated with Low-Toxicity QS-21-Containing Liposomes. Bioconjug Chem. 2023;34:893–910.

Article  CAS  PubMed  PubMed Central